Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations

NCT: NCT03243019 · RECRUITING

NCT IDNCT03243019
StatusRECRUITING
Start Date2018-06-25
Completion2027-02

Brief Summary

To evaluate the efficacy of Rapamycin in extended cervicofacial lymphatic malformations in pediatric patients. Rapamycin is administered oral for a 6 month period. The success rate is determined by volume reduction superior to 1/5e of the initial volume measured by MRI, impact on QOL and reduction of bleeding in case of mucosal involvement.

Frequently Asked Questions

What is Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations?

Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations is a clinical trial registered under NCT03243019. Current status: RECRUITING.

What is the status of NCT03243019?

The current status of NCT03243019 (Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations) is: RECRUITING.

When did Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations start?

Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations started on 2018-06-25.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑